乌帕替尼治疗重度斑秃12例短期疗效观察  

Short term efficacy of Upatinib in the treatment of 12 patients with severe alopecia areata

作　　者：尚智伟[1] 汪文翠 夏丽晔 SHANG Zhiwei;WANG Wencui;XIA Liye(First Affiliated Hospital,College of Clinical Medicine of Henan University of Science and Technology,Luoyang 471003,China)

机构地区：[1]河南科技大学临床医学院河南科技大学第一附属医院,河南洛阳471003

出　　处：《皮肤性病诊疗学杂志》2024年第8期542-545,共4页Journal of Diagnosis and Therapy on Dermato-venereology

摘　　要：目的 观察乌帕替尼治疗重度斑秃的短期临床疗效及安全性。方法 纳入2023年3月—2024年3月河南科技大学第一附属医院皮肤科门诊12例重度斑秃患者,给予口服乌帕替尼缓释片治疗,12周后观察临床疗效和不良反应情况。结果 治疗12周后,脱发严重程度评估工具评分(SALT)≤20分的患者达到10例(83.33%);毛发平均密度由(29.42±3.23)根/0.46 cm^(2)增加至(35.50±2.87)根/0.46 cm^(2),差异有统计学意义(t=27.62,P<0.001);毛发平均直径由(39.58±2.35)μm增加至(67.75±6.43)μm,差异有统计学意义(t=14.26,P<0.001)。所有患者均未发生严重不良反应。结论 乌帕替尼治疗重度斑秃疗效显著,安全性好,可作为重度斑秃患者新的治疗选择。Objective To observe short term efficacy and safety of Upatinib in the treatment of severe alopecia areata.Methods From March 2023 to March 2024,12 patients with severe alopecia areata were treated orally with sustained-release tablets of Upatinib at the dermatology outpatient clinic of the First Affiliated Hospital of Henan University of Science and Technology.After 12 weeks of the treatment,the clinical efficacy and adverse reactions were evaluated.Results After 12 weeks of the treatment,there were 10 patients(83.33%)with SALT≤20 points.The average hair density was increased from 29.42±3.23/0.46 cm^(2) at baseline to 35.50±2.87/0.46 cm^(2)(t=27.62,P<0.001).The average hair diameter was also increased from(39.58±2.35)μm to(67.75±6.43)μm(t=14.26,P<0.001).No serious adverse reactions were observed in all patients.Conclusions Upatinib is effective and safe for severe alopecia areata,and can be an optional therapeutic approach for severe alopecia areata.

关 键 词：乌帕替尼 斑秃 重度 疗效观察 

分 类 号：R758.71[医药卫生—皮肤病学与性病学]